| 0.6299 0.055 (9.47%) | 10-09 15:47 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.78  |
1-year : | 0.87 |
| Resists | First : | 0.66 |
Second : | 0.75 |
| Pivot price | 0.58 |
|||
| Supports | First : | 0.53 | Second : | 0.44 |
| MAs | MA(5) : | 0.59 |
MA(20) : | 0.58 |
| MA(100) : | 1.9 |
MA(250) : | 2.69 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 56.4 |
D(3) : | 54.3 |
| RSI | RSI(14): 29.1 |
|||
| 52-week | High : | 13.94 | Low : | 0.53 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PPBT ] has closed It is unclear right now based on current values. 91.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.59 - 0.59 | 0.59 - 0.6 |
| Low: | 0.56 - 0.57 | 0.57 - 0.57 |
| Close: | 0.57 - 0.58 | 0.58 - 0.58 |
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
Fri, 19 Sep 2025
Purple Biotech Enters New ATM Agreement with H.C. Wainwright - TipRanks
Fri, 05 Sep 2025
$18M Financing: Purple Biotech Secures $6M Public Offering Plus $12M in Short-Term Warrant Potential - Stock Titan
Fri, 05 Sep 2025
Purple Biotech Ltd. Closes $6 Million Public Offering of American Depositary Shares and Short-term Warrants - Quiver Quantitative
Thu, 04 Sep 2025
$18M Financing Deal: Purple Biotech Prices Public Offering with $1.00 Warrants for Cancer Drug Development - Stock Titan
Wed, 27 Aug 2025
Clinical-Stage Cancer Drug Developer Purple Biotech to Present at Major Healthcare Conference - Stock Titan
Wed, 27 Aug 2025
Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 503 (M) |
| Held by Insiders | 6.6 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 175 (K) |
| Shares Short P.Month | 103 (K) |
| EPS | -45.91 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -10.3 % |
| Return on Equity (ttm) | -8.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.01 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.02 |
| PEG Ratio | 0 |
| Price to Book value | 10.31 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|